Inhibikase Announces Expansion of Senior Leadership Team [Yahoo! Finance]
Inhibikase Therapeutics, Inc. (IKT)
Company Research
Source: Yahoo! Finance
--- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension (“PAH”) to its senior leadership team. Chris Cabell, M.D., former Chief Medical Officer of Arena Pharmaceuticals and Chief Executive Officer of CorHepta Pharmaceuticals, Inc. (“CorHepta”) has been appointed as President and Head of Research & Development. Additionally, CorHepta co-founder and former Head of Research at Arena Pharmaceuticals, John Adams, Ph.D. has been appointed Chief Scientific Officer. “Chris and John are outstanding scientific leaders with established track records in pulmonary arterial hypertension,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “Additionally, we expect these key executives will en
Show less
Read more
Impact Snapshot
Event Time:
IKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKT alerts
High impacting Inhibikase Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IKT
News
- Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $4.00 price target on the stock.MarketBeat
- Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.MarketBeat
- Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
IKT
Earnings
- 8/14/25 - Miss
IKT
Sec Filings
- 12/19/25 - Form 8-K
- 12/19/25 - Form 424B5
- 11/24/25 - Form 4
- IKT's page on the SEC website